All 24 patients completed treatment with no dose-limiting toxicities, no Grade 3 or higher adverse events related to JNJ-1900 (NBTXR3 or to the injection procedure, and intratumoral injection was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results